SCHEMBL18519692

SCHEMBL18519692

CON(C)C(=O)C1CCCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.58
RECQL P46063 1/20 0.49
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
EPHX1 P07099 1/20 0.46
HSD17B10 Q99714 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN6 P29350 1/20 0.45
ABL1 P00519 1/20 0.45
RIN1 Q13671 1/20 0.45
STS P08842 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR119 Q8TDV5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23727040 1.00 HPGD (0.58) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL407899 0.94 HPGD (0.56) HPGDRECQLKMT2AALDH1A1MAPT
SCHEMBL968401 0.89 MEN1 (0.56) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL3730650 0.89 HPGD (0.51) HPGDRECQLKMT2AALDH1A1EPHX1
SCHEMBL442932 0.89 MEN1 (0.56) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL1249710 0.89 MEN1 (0.56) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL389962 0.86 HPGD (0.54) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL894559 0.86 HPGD (0.54) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL586312 0.86 HPGD (0.54) HPGDRECQLKMT2AALDH1A1MEN1
SCHEMBL4842173 0.86 HPGD (0.48) HPGDRECQLKMT2AALDH1A1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217964-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. 2024-07-04 US disclosed
CN-116034107-A Quinuclidinone analogs as anticancer agents 新波制药有限公司 2023-04-28 CN disclosed
US-20230089530-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. 2023-03-23 US disclosed
EP-4100407-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS Newave Pharmaceutical Inc. (US) 2022-12-14 EP disclosed
WO-2022204109-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. (US) 2022-09-29 WO disclosed
WO-2021158948-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. (US) 2021-08-12 WO disclosed
WO-2017024996-A1 HYDROXY AMIDINE DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF 江苏恒瑞医药股份有限公司 2017-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089530-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NQO2, CNKSR1, NQO1 HPGD 1471/4885RECQL 72/4885KMT2A 212/4885
US-20240217964-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NQO2, PRMT1, PRMT7 HPGD 1500/4885RECQL 28/4885KMT2A 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.